PARP inhibitor combination therapy

Crit Rev Oncol Hematol. 2016 Dec;108:73-85. doi: 10.1016/j.critrevonc.2016.10.010. Epub 2016 Oct 31.

Abstract

In 2014, olaparib (Lynparza) became the first PARP (Poly(ADP-ribose) polymerase) inhibitor to be approved for the treatment of cancer. When used as single agents, PARP inhibitors can selectively target tumour cells with BRCA1 or BRCA2 tumour suppressor gene mutations through synthetic lethality. However, PARP inhibition also shows considerable promise when used together with other therapeutic agents. Here, we summarise both the pre-clinical and clinical evidence for the utility of such combinations and discuss the future prospects and challenges for PARP inhibitor combinatorial therapies.

Keywords: BRCA1; BRCA2; Drug combinations; PARP inhibitor.

Publication types

  • Review

MeSH terms

  • Animals
  • Drug Combinations
  • Humans
  • Immunotherapy
  • Neoplasms / drug therapy
  • Neoplasms / enzymology
  • Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use*
  • Poly(ADP-ribose) Polymerases / metabolism

Substances

  • Drug Combinations
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Poly(ADP-ribose) Polymerases